Aethlon Medical (AEMD) announced that the independent Data Safety Monitoring Board overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review of the second cohort participant data and recommended advancing to the third and final cohort. They also stated that “no safety concerns were noted with Hemopurifier device/procedure”. The trial, titled “Safety, Feasibility, and Dose-Finding Study of Aethlon Hemopurifier in Patients with Solid Tumors Who Have Stable or Progressive Disease While on a Treatment That Includes Pembrolizumab or Nivolumab”, is being conducted to assess the Hemopurifier’s safety, feasibility, and optimal dosing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AEMD:
- Aethlon Medical Completes Pre-Funded Warrant Exercises, Simplifying Equity
- Aethlon Medical to evaluate range of strategic opportunities
- Aethlon Medical Shareholders Approve Share Expansion and Governance
- Aethlon Earnings Call Balances Trial Progress With Cash Risk
- Aethlon Medical Posts Q3 Results, Highlights Hemopurifier Progress